Twitter Updates

    follow me on Twitter

    Tip Jar

    Change is Good

    Tip Jar
    Blog powered by Typepad
    Member since 07/2009

    « ASCO 2010 Starts Today in Chicago | Main



    Feed You can follow this conversation by subscribing to the comment feed for this post.

    so good place at here, thanks.I can not believe that, the imformation is so helpful for me.

    At Sunday’s Plenary Session, a landmark study provided new data that have implications for changing clinical practice. Steven O’Day, MD, of the Angeles Clinic and Research Institute, reported that ipilimumab alone or in combination with vaccine increased overall survival (OS) in patients with unresectable stage III/IV melanoma for whom previous treatment had failed (Abstract 4). “This is an historic first — the first phase III randomized study showing improvement in median and long-term survival in patients with metastatic melanoma,” Dr. O’Day said. Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte antigen 4 (CTLA-4), is an immune therapy directed against T-cells. The...

    I love to come back and read
    metro electronic cigarette

    Good day and welcome to check:

    The comments to this entry are closed.